Molecule in cruciferous veggies may protect against lung infection

Share on PinterestA recent study shows that molecules naturally found in cruciferous vegetables may protect the lungs from illness. skaman306/Getty Images Research has shown that consuming a variety of vegetables provides a number of health benefits when consumed. A recent study shows that molecules naturally found in cruciferous vegetables may help the lungs maintain a healthy barrier against infection. The findings suggest that eating cruciferous veggies like leafy greens and broccoli could bolster immunity and preserve lung health. For a very long time, doctors have urged people to eat more vegetables. Not only are they nutritious, but previous research shows adding more veggies to a person’s diet can help reduce obesity risk, improve mental health, lower heart disease risk, and boost gut health. In a recent study, researchers from the Francis Crick Institute in London have found that molecules naturally found in cruciferous vegetables — such as broccoli and cauliflower — can boost the activity of a protein called aryl hydrocarbon receptor (AHR), helping the lungs to maintain a healthy barrier against viral and bacterial infection. The findings were recently published in the journal Nature. Aryl hydrocarbon receptor (AHR) is a type of cellular protein. In the body, it assists with gene regulation and the metabolism of certain enzymes. Previous research also shows AHR plays a role in regulating the immune system and plays an active role in stem cells. Because of its relation to the immune system, scientists have studied the use of AHR as a potential target for prevention and therapies for a number of diseases, including: In this study, researchers focused on the natural lung barrier that helps protect the lungs from pollution and infection. The lung barrier includes two layers — one of endothelial cells and one of epithelial cells. This allows the barrier to keep out viruses and bacteria but still lets oxygen enter. According to Dr. Andreas Wack, PhD, principal group leader of the Wack Lab Immunoregulation Laboratory at the Francis Crick Institute and lead author of this study, they decided to study the effect of AHR on lung barriers because it has been studied extensively at other barrier sites such as the skin and the gut, but much less so in the lung. “AHR is an environmental sensor that can be activated by ligands found in food or produced by bacteria living in our gut — but some toxic ligands are also derived from air pollution. AHR protects the lung by inducing gene programs known to support barrier integrity and barrier function. Which genes are directly targeted by AHR and which ones are triggered indirectly is unclear.” — Dr. Andreas Wack, PhD, lead study author For the present study, Dr. Wack and his team performed a variety of experiments using a mouse model. When mice were infected with the flu virus, scientists found blood in the airspaces in the lungs as it had leaked across the damaged lung barrier. When AHR was overactivated, there was less blood in the lung spaces, indicating that it helped prevent the lung barrier from leaking. During the study, scientists observed mice with increased AHR activity did not lose as much weight when infected with the flu virus. Additionally, the AHR-enhanced mice could better fight off bacterial infection and the already-introduced flu virus. Researchers also found the flu infection caused a decrease in protective lung AHR activity only in mice fed AHR ligands in their diet before the illness. Mice that consumed an AHR ligand-rich diet during infection had better lung barrier integrity and less lung damage than those on a control diet. “In mice without ligands in the diet, their AHR activity levels were low to start with, so if you don’t eat ligands, you have little AHR activity,” Dr. Wack explained to Medical News Today. “When you eat them, then AHR activity increases. This activity can be dampened by sick behavior, i.e., not eating for some days.” “This is probably not a good idea, so keep eating a healthy diet to upkeep AHR activity,” he added. “What is good for your gut — a healthy, rich, (and) varied diet containing AHR ligands — is probably also good for your lungs.” After reviewing this study, Dr. Elliot Eisenberg, assistant professor of medicine (pulmonary, critical care, and sleep medicine) at the Icahn School of Medicine at Mount Sinai, told MNT that the data was encouraging and demonstrated a potential protective effect of dietary intake on lung endothelial cell response to infection. “As this is preclinical data, dietary recommendations for patients with influenza cannot be made,” Dr. Eisenberg said. “[The study data] does provide biological plausibility to support future clinical and translational endeavors assessing diet and clinical outcomes and adds to the growing body of literature supporting the role of diet and lung health.” “Prior clinical research, including studies by Mount Sinai, have demonstrated healthy diet attenuates wheezing among teens with secondhand smoke exposure, and is associated with (a) slower decline in lung function amongst young adults.” — Dr. Elliot Eisenberg, pulmonary and internal physician Cruciferous vegetables are part of a family of vegetables known as brassicas. There are more than 3,000 different types of cruciferous vegetables. The most commonly known are: In addition to providing the nutritional benefits all vegetables are known for, these veggies are also high in dietary fiber and rich sources of specific vitamins, including vitamins C, E, K, and B9 (folate). Cruciferous vegetables also contain phytonutrients, which are compounds known to help lower inflammation. Previous studies have also linked phytonutrients to cancer treatment and prevention. And these types of veggies naturally have chemicals called glucosinolates. Past studies have linked glucosinolates to potential cancer protection, such as gastrointestinal cancers. Additionally, other studies have looked at using glucosinolates to help protect against cardiovascular and neurodegenerative diseases. Health and nutrition experts recommend consuming 2 to 3 cups of vegetables daily as part of a healthy, balanced diet.

Breakthrough blood test can detect infection causing a child’s fever in just one hour

A blood test that can determine in less than an hour which infection has made a child feverish has been developed by British scientists. It is hoped the test created at Imperial College London could be available on the NHS within five years and speed up potentially life-saving diagnoses. There is currently no easy way to know what is causing a child to be hospitalised with a high fever as it could be the result of numerous bacteria, viruses or inflammatory diseases. The proof of concept test created by Imperial screens whole blood samples to find out what genes have been switched off by an infection, thereby revealing the cause. It can give accurate results in less than 60 minutes as opposed to the current approach of doing specialised individual tests that can take several days to provide a diagnosis. Quicker diagnosis and treatment Scientists say the findings could help speed up diagnosis and treatment of sick paediatric patients while also preventing incorrect prescriptions and overuse of antibiotics fuelling antimicrobial resistance. Researchers analysed data from 1,212 patients who were known to have 18 different types of disease – ranging from malaria and Kawasaki disease to Strep B, flu and tuberculosis – and identified 161 genes of interest. Live tests on more than 400 febrile children showed the test worked and was able to detect what was making them sick. Scientists are now trying to make the laboratory-based blood test commercially viable and able to be deployed in hospitals at scale. “In the paper we used gene expression microarrays and RNA-sequencing to quantify the genes and provide diagnosis for the patients,” Dr Myrsini Kaforou, the study author and infectious disease expert at Imperial, told the Telegraph. “However we are now working with the company Biomerieux as part of our Diamonds H2020 funded research collaboration to optimise and translate this approach for use in hospital testing.” She added that the technology is being refined and simplified with fewer genes needed for the analysis to “optimise for clinical settings”. “We are hoping that within five years it could be used in the NHS and could make a difference particularly for conditions for which diagnostic tests are not available like Kawasaki disease,” she said. Prevent overuse of antibiotics It is hoped the new test could tackle the overuse of antibiotics in children which are usually prescribed until an antibacterial infection can be ruled out. Prof Michael Levin, the chair of paediatrics and international child health within Imperial College London’s department of infectious diseases, said the test could help make vital decisions with accuracy and speed. “Despite huge strides forward in medical technology, when a child is brought into hospital with a fever, our initial approach is to treat based on the doctor’s ‘impression’ of the likely causes of the child’s illness,” he said. “As clinicians, we need to make rapid decisions on treatment, often just based on the child’s symptoms, information from the parents, and our medical training and experience, but we may not know whether a fever is bacterial, viral, or something else until hours or days after a child has been admitted when their test results come back. “Such delays can stop patients getting the right treatment early on, so there is a clear and urgent need to improve diagnostics.” Dr Kaforou said there is “still much work to be done” to progress the test into clinical settings, but the team is “working towards it”. “A future diagnostic test based on this approach could help provide the right treatment, to the right patient, at the right time, while optimising antibiotic use and reducing lengthy time to diagnosis for inflammatory diseases,” she said. The study is published in the journal Cell Press Med.

Blood test could tell if a fever is due to infection or other diseases

Many childhood fevers are due to undiagnosed illnesses, but a blood test can identify potential causes Shutterstock/Aleksandra Suzi A blood test can determine whether a fever is caused by bacteria, viruses or an inflammatory disease using changes in gene activity. About two-thirds of children hospitalised for fever don’t receive a diagnosis. Current diagnostic tools, which look for pathogens, are slow and sometimes unreliable, says Myrsini Kaforou at Imperial College London. Genetic tests are a promising alternative as certain genes switch on or off in response to disease. Kaforou and her colleagues examined the genetic analysis of blood samples from 1212 children who were between a few weeks to 18 years old. All had been diagnosed with one of 18 infectious or inflammatory diseases that cause fever. Advertisement The researchers used a machine learning model to analyse this data, and identified 161 genes that correlate with diseases across six categories: bacterial infections, viral infections, inflammatory diseases, malaria, tuberculosis or Kawasaki disease. The researchers validated the model in a separate group of 411 children with fever, and assessed it using a statistical measure that estimates accuracy on a scale of 0 to 1. Across the disease categories, the team found that the model had a score of 0.89 to 1 – generally, a score of 0.8 or higher indicates excellent accuracy. The finding could speed up diagnoses, ensure appropriate treatment and reduce unnecessary antibiotic use, which contributes to antibiotic resistance, says Kaforou. “This is a meaningful step in the right direction for precision medicine in infectious and inflammatory diseases in children,” says Christopher Woods at Duke University in North Carolina. However, validation in larger datasets is necessary before it can be used in clinical settings, he says. “Obviously, this is not a full list of every single infectious and inflammatory disease out there,” says Kaforou. “At the moment, we are recruiting more patients and generating more data to identify a signature that covers even more infectious and inflammation conditions.” Topics:

Belzutifan Improves Key Outcomes of LITESPARK-005 in Adults With Advanced RCC

Eric Jonasch, MD Treatment with belzutifan (Welireg) led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with everolimus (Afinitor) in adult patients with advanced renal cell carcinoma (RCC) whose disease progressed following PD-1/PD-L1 and VEGF tyrosine kinase inhibitor (TKI) treatments, according to a press release.1 The primary end point of the phase 3 LITESPARK-005 study (NCT04195750) was met with this result, and the study also met a key secondary end point with belzutifan demonstrating significant improvement in overall response rate (ORR) compared with everolimus. Although not statistically significant, belzutifan also showed a trend toward improvement in overall survival (OS) vs everolimus. Results come from the prespecified interim analysis of LITESPARK-005. The safety portion of the analysis showed that belzutifan’s profile was consistent with that shown in prior studies. Full results will be presented at an upcoming medical meeting and shared with regulatory bodies. “Based on the data in patients with von Hippel-Lindau [VHL] disease, and on the phase 1b/2 study we conducted in patients with previously treated advanced RCC, it became clear belzutifan is an active drug,” Eric Jonasch, MD, professor in the department of genitourinary medical oncology, division of cancer medicine, at The University of Texas MD Anderson Cancer Center in Houston, TX, told Targeted Oncology™. “This registrational study, where patients with treatment-refractory clear cell RCC were randomized between belzutifan and everolimus, was conducted with the goal of obtaining approval for belzutifan in the refractory disease setting.” cancer cell | Image Credit: © catalin – www.stock.adobe.com The data rationalizing the exploration of belzutifan in previously treated advanced RCC were from LITESPARK-004 (NCT03401788). According to findings presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, belzutifan achieved anti-tumor activity and consistent safety in patient with VHL-related neoplasms. Of the 61 patients in the study, 83% had hemangioblastoma, and 33% had pancreatic neuroendocrine tumors (pNETs).2 The ORR in the hemangioblastoma cohort was 59% with a complete response (CR) rate of 3% and a partial response (PR) rate of 56%. The median duration of response (DOR) observed with belzutifan in the VHL population was not reached (range, 8.3+ to 27.6+ months). For the pNETs cohort, the ORR was 90%, with CRs in 3 patients and PRs in 15. The median DOR was not reached (range, 11.0+ to 31.0+ months). Sixteen percent of patients in the LITESPARK-004 study experienced grade 3 treatment-related adverse events (TRAEs). The most common TRAE was anemia, which occurred in 10% of patients. There were no grade 4 or 5 TRAEs during the study. Two patients discontinued treatment due to a TRAE. LITESPARK-005 is an open-label, randomized, phase 3 study in which patients are randomly assigned to receive oral belzutifan at 120 mg once daily or oral everolimus at 10 mg once daily. In addition to PFS, the study explores a coprimary end point of OS, and secondary end points other than ORR include DOR, the number of patients with adverse events, treatment discontinuation rate, and quality of life (QOL). QOL will be determined by several measure including time to deterioration (TTD) in health-related QOL, TTD in physical functioning, TTD in disease symptoms, change from baseline in health-related QOL, change from baseline in physical functioning, and change from baseline in European Quality of Life 5 Dimensions.3 The trial aims to enroll 746 patients with previously treated advanced RCC who meet the criteria. For inclusion, patients must have evidence of unresectable, locally advanced, metastatic disease, must have had disease progression on or after systemic therapy with a PD-1/PD-L1 inhibitor, must have received 3 prior systemic regimens for locally advanced or metastatic RCC, and have adequate organ function. All patients are required to use contraception once on the study, and female patients cannot be pregnant prior to starting therapy. “Patients with advanced RCC face low survival rates, and for those whose cancer progresses following PD-1/L1 and VEGF-TKI therapies, there is a need for new treatment options that can reduce their risk of disease progression or death,” said Marjorie Green, MD, senior vice president and head of late-stage oncology, global clinical development at Merck Research Laboratories, in a press release.1 “This is the first phase 3 trial to show positive results in advanced RCC following these therapies and the first new mechanism to demonstrate potential in advanced RCC in recent years. We look forward to discussing these results with health authorities.” “If these data lead to the approval of belzutifan for the treatment of refractory RCC, it provides patients and practitioners with an active, well-tolerated treatment option when patients progress on prior lines of therapy. The [AE] profile, with anemia, fatigue and hypoxemia being most common AEs, is easily manageable, making it an attractive choice,” said Jonasch. REFERENCES: 1. Merck Announces Welireg® (belzutifan) phase 3 LITESPARK-005 trial met primary endpoint of progression-free survival in certain previously treated patients with advanced renal cell carcinoma. News release. Merck, August 18, 2023. Accessed August 18, 2023. https://tinyurl.com/5duv497t 2. Jonasch E, Iliopolous O, Rathmell WK, et al. LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data. J Clin Oncol. 2022;40(suppl 16):4546. doi:10.1200/JCO.2022.40.16_suppl.4546 3. A study of belzutifan (MK-6482) versus everolimus in participants with advanced renal cell carcinoma (MK-6482-005). ClinicalTrials.gov. Updated August 1, 2022. Accessed August 18, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT04195750

Did Vlad the Impaler, Inspiration for Dracula, Shed Tears of Blood?

FRIDAY, Aug. 18, 2023 (HealthDay News) – The 15th century prince who inspired the literary vampire Dracula may have had medical issues that caused him to cry tears of blood, according to researchers unearthing this ancient mystery. The prince, who was also a military leader, was known as Vlad III, Voivode of Wallachia and as Vlad the Impaler. He was also called Vlad Drăculea, translating to “the son of the dragon,” and may be the inspiration for the character Count Dracula.

Covid infections on the rise again in Germany, say experts

German epidemiologists are warning of a summer wave of coronavirus infections, blaming in part mass gatherings such as the Barbenheimer double feature craze. The government’s disease control agency, the Robert Koch Institute (RKI), says that while infections remain low compared with at the height of the pandemic, they have been on the rise for the past month. According to the government’s Pandemic Radar, which is updated daily by the health ministry, visits to the doctor due to a Covid 19 infection are up 175% on the previous week, with 2,400 cases reported to the RKI this week compared with 400 the previous week, and double the rate of a month ago. Hospital admissions of people with coronavirus are up 50%. And more than half of Germany’s monitoring stations, in particular sewage plants, have indicated a rise in viral load detected in wastewater this month. The number of official test results shows the rate to be low, at 3 in every 100,000 people. However, the figure itself is hardly a reflection of the real rate, as so few tests are now being carried out. “It could be that we’re having a summer wave,” Timo Ulrichs an epidemiologist at the Berlin Akkon University of Human Sciences, told the news portal Spiegel, adding that the so-called “Barbenheimer effect” was capable of boosting the numbers. Germany was among the countries where cinemagoers were encouraged to go to watch the blockbuster films Barbie and Oppenheimer as a double feature, in an effort to boost cinema attendance which has yet to recover since the pandemic. So far just under 4 million have seen Barbie, and over 2.5 million, Oppenheimer. The idea of a Barbenheimer effect on the spread of the virus was first playfully mooted by the vaccine expert Peter Hotez of the National School of Tropical Medicine at the Baylor College of Medicine in Texas. Suggesting on Twitter that it might be of concern, due to the millions of people surging to cinemas and spending hours in a windowless room together, he concluded: “We’ll probably never know since no one seems to be keeping track of such things any more.” New York has recently recorded a doubling in hospitalisations due to the EG.5 Eris variant of Omicron, which the World Health Organization last week classified as a “variant of interest”. Hotez urged people to keep up with their boosters and wear a pink medical mask – in a nod to Barbie – if they were planning a cinema visit. Germany’s health minister, Karl Lauterbach, said in reaction to rising levels elsewhere in the world, and the increase in Germany, where the XBB.1.5 variant is currently responsible for most new infections: “our early warning system is activated”. Germans are being encouraged to get booster jabs in the autumn, if they belong to a higher-risk group, such as those over 60, and people who are overweight, suffer from a lung disease such as COPD, or work in a risky environment such as a hospital. Those who are sick are being advised to stay at home.

The impact of regular exercise on cardiovascular health

In the heart of Onitsha, the picturesque town nestled between rolling hills and shimmering lakes, lived a vibrant young woman named Chiamaka. Chiamaka was a dedicated kindergarten teacher, whose warm smile and caring nature won the hearts of all her students. Despite her cheerful demeanor, Chiamaka had been carrying a secret burden—she was diagnosed with coronary heart disease at a young age. Chiamaka’s condition had been a wake-up call for her and her family. They realized the importance of making healthy lifestyle choices to manage the disease effectively. Driven by her passion for teaching and her desire to lead a fulfilling life, Chiamaka took charge of her health. She consulted with her doctors regularly, followed a balanced diet, and most importantly, embraced the transformative power of regular exercise. One fateful morning, Chiamaka decided to start her day with a refreshing walk around her street. The crisp air filled her lungs, and she relished the soothing sounds of birds singing in harmony. As she walked, she noticed a flyer on the community notice board—Dr. Chima Azubuike, the renowned psychologist of Onitsha, was organizing a series of mindfulness and exercise workshops to promote cardiovascular health. Emily’s heart raced with excitement, and she knew she had to be a part of it. The workshops were held in the park every weekend, and soon, Emily became a regular participant. Dr. Azubuike, along with a team of fitness experts, introduced various physical activities, including yoga, aerobics, and meditation. Each session focused not only on the physical aspects of exercise but also on its profound impact on emotional well-being. As weeks passed, Chiamaka felt a remarkable change within herself. Not only did she notice improvements in her physical stamina, but her mind felt calmer and more resilient. The stress and anxiety that had once weighed heavily on her heart began to dissipate. She forged new friendships with fellow participants, creating a support system that uplifted her spirit. One sunny morning, during a guided meditation, Chiamaka experienced a breakthrough. She visualized her heart as a radiant, strong, and healthy organ, pulsating with vitality. Tears of joy streamed down her cheeks as she realized that she held the power to nurture her heart and heal her body. Word about the transformative workshops spread throughout Onitsha, drawing more participants each week. The community became a tapestry of individuals, young and old, coming together to support each other on their journey to better cardiovascular health. Dr. Azubuike’s wisdom and guidance nurtured not only their physical well-being but also the sense of unity and camaraderie among them. Chiamaka’s story inspired many, and the ripple effect of her transformation extended beyond the workshops. Local schools and businesses began incorporating fitness programs into their routines, and the town’s parks saw an influx of families engaging in outdoor activities. Onitsha became a shining example of how a small community could embrace change and prioritize the well-being of its residents. Regular exercise has a profound impact on cardiovascular health, and numerous studies have demonstrated the positive relationship between physical activity and a reduced risk of coronary heart disease (CHD). Engaging in regular exercise promotes a healthier heart, improves circulation, lowers blood pressure, and reduces the risk of various cardiovascular conditions. 1. Strengthening the Heart: Regular exercise, especially aerobic activities like walking, running, and cycling, helps to strengthen the heart muscle. As individuals engage in physical activity, the heart pumps more blood, leading to an increase in stroke volume—the amount of blood ejected with each heartbeat. Over time, this strengthens the heart, enabling it to pump more efficiently and maintain a healthier blood flow. 2. Lowering Blood Pressure: High blood pressure is a significant risk factor for heart disease. Exercise helps to reduce blood pressure by promoting the relaxation and dilation of blood vessels, which in turn eases the strain on the heart. Lower blood pressure translates to a reduced risk of heart attacks, strokes, and other cardiovascular complications. Read also: Making your money work: Understanding time value of money in personal finance 3. Managing Cholesterol Levels: Regular physical activity has been shown to positively impact cholesterol levels. It helps to increase high-density lipoprotein (HDL) cholesterol, often referred to as “good cholesterol,” which helps remove low-density lipoprotein (LDL) cholesterol, or “bad cholesterol,” from the bloodstream. This balance of cholesterol levels plays a crucial role in preventing the formation of plaque in the arteries, reducing the risk of atherosclerosis. 4. Enhancing Circulation: Exercise promotes better circulation, allowing the blood to deliver oxygen and nutrients more efficiently throughout the body. Improved circulation helps maintain healthy blood vessels and reduces the risk of blood clots, which can lead to heart attacks and strokes. 5. Stress Reduction and Mental Well-being: Physical activity has an immense impact on emotional well-being, as exemplified in the story of Chiamaka. Regular exercise releases endorphins—natural mood elevators—reducing stress, anxiety, and depression. The positive mental state, in turn, contributes to better cardiovascular health by lowering the risk of stress-related heart conditions. In conclusion, the story of Chiamaka and the heartwarming transformation of Onitsha exemplify the powerful role regular exercise plays in the management of coronary heart disease. Embracing physical activity not only strengthens the heart and enhances cardiovascular health but also fosters a sense of community and emotional well-being. Whether in a small town or a bustling city, prioritising regular exercise can lead to a healthier, happier, and more connected society, where the heartbeat of change resonates with hope and vitality.

CBCO blood drive planned at TCMH

This story has Unlimited Access. Please support our commitment to public service journalism. Subscribe now. Texas County Memorial Hospital is hosting a blood drive from 9 a.m. until 3 p.m. Friday, Sept. 8. Community Blood Center of the Ozarks (CBCO) will collect blood donations in the Jayson Gentry Community Safe Room on the TCMH campus. TCMH receives 100 percent of its blood supply from CBCO. All blood collected by CBCO stays in the area to be utilized by Ozark communities, neighbors and families. The CBCO serves TCMH and 43 other hospitals in 40 different counties. Approximately 250 units of blood are needed each day. TCMH uses about 400 units of blood each year. Eligible donors can be anyone 16 years old (requires parental consent for first-time donors) or older who weighs at least 110 pounds and has not been given blood in the last 56 days. All donors must provide identification when registering to donate. Donors will receive an exclusive “Be a Party Animal – Go Wild” blood drive T-shirt and two tickets to Dickerson Park Zoo in Springfield while supplies last. Appointments are not required; however, strongly encouraged to manage donor flow. To schedule your appointment, call CBCO at 417-227-5006 or go to www.cbco.org/donate-blood. For more information about the blood drive, contact Jason Mayberry, education director at TCMH, at 417-967-1340 or 866-967-3311. For questions regarding donor eligibility, contact the CBCO at 800-280-5337.

Zalgen Immunotherapeutic Confers Complete Protection Against Advanced Multilineage Lassa Infections in Nonhuman Primates

Article in Proceedings of the National Academy of Sciences (PNAS) reports data from the latest study at the University of Texas Medical Branch at Galveston (UTMB) showing protection against Lassa Fever, a significant threat to global health. FREDERICK, Md., Aug. 18, 2023 /PRNewswire/ — Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, including Lassa Fever (LF), today announced publication of data demonstrating that Arevirumab-3®, its lead immunotherapeutic candidate, is an effective therapeutic for the treatment of Lassa virus infections, with activity against all major viral lineages that cause severe disease in humans, and at very low dosages. The study emanated from an extensive and ongoing research collaboration of Zalgen, Tulane University (Tulane), UTMB, and other members of the Viral Hemorrhagic Fever Consortium (VHFC) [www.vhfc.org] and the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC) [www.vhfimmunotherapy.org] working on advanced alternatives to treat Lassa fever and other hemorrhagic viral infections. The just released publication: A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus, Cross RW, et al. (DOI number 10.1073/pnas.2304876120) is the latest in a series of scientific reports from Zalgen studies at UTMB. This study, in conjunction with the previously reported high-resolution structures of Arevirumab-3 antibodies, docked on the viral glycoprotein (Li H et al. A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus. Sci Transl Med. 2022 Oct 26;14(668)) form the core of a recently reviewed pre-Investigational New Drug (pre-IND) application by the U.S. Food and Drug Administrations (FDA). Arevirumab-3 is now on a path toward IND, with projected Phase 1 clinical studies to assess the safety and immunogenicity of the drug in healthy human subjects. “The ultimate goal of this program is to complete the clinical evaluation of Arevirumab-3 as a novel drug for the treatment of active Lassa fever, as well as its potential use as a prophylactic,” stated Luis M. Branco Ph.D., Zalgen Managing Director. “Arevirumab-3 is the first drug to be developed specifically for the treatment of Lassa fever, a viral hemorrhagic fever widely regarded as a leading pandemic concern.” Lassa fever is a dangerous, often fatal disease common to much of West Africa, with children and pregnant women being the highest risk groups; the early stages of the disease are difficult to distinguish from other diseases. Lassa fever is spread by contact with infected rodents and is estimated to infect 300,000 to 500,000 people per year across the region, with at least 5,000 deaths annually. The illness is characterized by bleeding and coagulation abnormalities, with mortality rates reported exceeding 25 percent and reaching 50 percent during epidemics. “The results of these studies demonstrating 100% effectiveness in monkeys more than a week after infection with Lassa virus suggests that this therapy may benefit patients with Lassa fever in West Africa, who often present to the clinic at a late stage of disease,” said Robert F. Garry, Ph.D., Co-Founder of Zalgen. The current study established that Arevirumab-3 is poised to offer a therapeutic option for a viral hemorrhagic fever that causes significant mortality and morbidity throughout the West African subcontinent, and for which there are very limited and largely ineffective options. Zalgen, UTMB, and Tulane are conducting additional studies to explore further the utility of Arevirumab-3 against divergent and emerging strains of the Lassa virus. The development path of Arevirumab-3 exemplifies how state-of-the-art complex immunotherapeutics are developed, tested, and progress toward human use. Development of Aruvirumab-3 was supported by the National Institutes of Health (NIH) grants BAA NIAID-DAIT-NIHAI2008031, 1R01AI104621-01, 1U19AI109762-01, 1R01AI132223-01, 1R43AI120472-01, and peripherally by 5R44AI115752-02, 1U01AI082119-01, and 1UC1 AI067188-01. About Zalgen LabsZalgen Labs is a biotechnology and diagnostics company headquartered in Frederick, Md., and an advanced diagnostic product development center in Aurora, Colo. The company specializes in the design and production of superior biological molecules critical for developing and commercializing immunotherapeutics, novel vaccines, and reliable, rapid, and affordable diagnostic platforms targeting neglected and underrepresented human infectious diseases. For more information, visit www.zalgen.com. SOURCE Zalgen Labs